Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (31-40 of 206) with videos related to

Pageof 21
Sort By:
Expert Opinion on Investigational Drugs|January 31, 2022
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?Christian Mayr, Tobias Kiesslich, Dominik Paul Modest, et al.
Annals of Surgical Oncology|June 25, 2010
Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumorsSebastian Stintzing, Ralf-Thorsten Hoffmann, Volker Heinemann, et al.
Annals of Vascular Surgery|April 9, 2005
Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosisSebastian Stintzing, Peter Heuschmann, Letterio Barbera, et al.
Cancers|January 23, 2024
Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal CancerAlexander Sebastian Franzén, Abdelhadi Boulifa, Clarissa Radecke, et al.
Cancers|April 12, 2022
Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical TranslationDino Bekric, Matthias Ocker, Christian Mayr, et al.
The Oncologist|August 25, 2021
Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal CancerJörg Trojan, Sebastian Stintzing, Oliver Haase, et al.
Journal of Medical Economics|January 7, 2020
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of <i>RAS</i> wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) studySebastian Stintzing, Ilse van Oostrum, Chris P Pescott, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 11, 2020
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant TreatmentPetra Ganschow, Lena Hofmann, Sebastian Stintzing, et al.
Frontiers in Oncology|February 23, 2023
Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancerChiara Cremolini, Clara Montagut, Philippe Ronga, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2015
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)Volker Heinemann, Sebastian Stintzing, Dominik P Modest, et al.
Pageof 21

Showing results (31-40 of 206) with videos related to

Sort By:
Pageof 21
Expert Opinion on Investigational Drugs|January 31, 2022
Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?Christian Mayr, Tobias Kiesslich, Dominik Paul Modest, et al.
Annals of Surgical Oncology|June 25, 2010
Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumorsSebastian Stintzing, Ralf-Thorsten Hoffmann, Volker Heinemann, et al.
Annals of Vascular Surgery|April 9, 2005
Overexpression of MMP9 and tissue factor in unstable carotid plaques associated with Chlamydia pneumoniae, inflammation, and apoptosisSebastian Stintzing, Peter Heuschmann, Letterio Barbera, et al.
Cancers|January 23, 2024
Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal CancerAlexander Sebastian Franzén, Abdelhadi Boulifa, Clarissa Radecke, et al.
Cancers|April 12, 2022
Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical TranslationDino Bekric, Matthias Ocker, Christian Mayr, et al.
The Oncologist|August 25, 2021
Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal CancerJörg Trojan, Sebastian Stintzing, Oliver Haase, et al.
Journal of Medical Economics|January 7, 2020
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of <i>RAS</i> wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) studySebastian Stintzing, Ilse van Oostrum, Chris P Pescott, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 11, 2020
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant TreatmentPetra Ganschow, Lena Hofmann, Sebastian Stintzing, et al.
Frontiers in Oncology|February 23, 2023
Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancerChiara Cremolini, Clara Montagut, Philippe Ronga, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2015
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)Volker Heinemann, Sebastian Stintzing, Dominik P Modest, et al.
Pageof 21